Grants & Programs

Development of Surrogate Endpoints for Cancer Immunotherapy Trials

October 05, 2014
07:00 AM
Grand Hyatt New York Hotel at Grand Central, New York, NY
View Map

This year, in conjunction with the CRI 22nd Annual International Cancer Immunotherapy Symposium, CRI hosted a special Cancer Immunotherapy Consortium (CIC) satellite meeting on Sunday, October 5, 2014, entitled Development of Surrogate Endpoints for Cancer Immunotherapy Trials.

The meeting consisted of a full day of presentations and panel discussions addressing the key rationale, challenges, and solutions surrounding the development of surrogate endpoints for cancer immunotherapy. This meeting represented the culmination of a CIC-led community-wide effort that brings together the major stakeholders in the field, including experts from industry, academia, and regulatory bodies as well as patients. The output of the meeting will be a consensus-driven roadmap for the efficient regulatory approval of future immunotherapies.